Financing Fuels the Company’s Hypergrowth to Make Elevated Care Accessible to More Patients Petrovic’s Appointment Positions Imperative Care for Long Term Success and Scale July 25, 2024 08:00 AM Eastern Daylight Time CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc., a medical technology company developing connected innovations to… Read More
Tulavi Therapeutics has received a de novo clearance from the FDA for a surgical kit designed to help reduce long-term phantom limb pains among people who have had an amputation. The Allay nerve cap system includes an absorbable hydrogel that encases the end of a severed nerve, preventing it from… Read More
Company’s first-in-class PDE9 inhibitor for heart failure and first-in-class CaMKII inhibitor move into later-stage clinical trials in cardiovascular diseases Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator Financing enables further expansion of pipeline and acceleration of capabilities as a cardiovascular drug innovator July… Read More
First-in-human Phase 1a/1b clinical trial will evaluate orally available, RGT-61159 designed to selectively target MYB RNA and inhibit oncogenic MYB protein production Preclinical data supporting the clinical trial were recently presented at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) WOBURN, Mass., July 10, 2024 /PRNewswire/ — Rgenta Therapeutics, a biotechnology… Read More
Series A co-led by Novartis Venture Fund and Delos Capital, with participation from OrbiMed, Insight Partners, J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics, Innovation Endeavors, Invus, Arc Ventures, and Deep Insight Company is developing a new class of genomic medicines based on naturally occurring genetic elements that may be… Read More
Financing led by BVF Partners LP, with participation from new investors RA Capital Management, Cormorant Asset Management, Soleus Capital, Delos Capital and existing investors aMoon Fund and Blackstone Multi-Asset Investing, among other new and existing investors Funds will be used to support ongoing and planned Phase 2a and 2b clinical… Read More
Financing led by SR One, NEA, Norwest Venture Partners, and Delos Capital with significant participation from Enavate Sciences, Longitude Capital, and other new and existing investors Proceeds to support ongoing mid- to late-stage clinical development programs for Company’s lead I&I product candidate, obexelimab WALTHAM, Mass, May 7, 2024 (GLOBE NEWSWIRE) – Zenas BioPharma,… Read More
SAN DIEGO, April 8, 2024 /PRNewswire/ — Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PT217 for the treatment of patients with extensive-stage small cell lung cancer… Read More
SAN DIEGO, CA & SHANGHAI, April 1st, 2024 – Sirius Therapeutics today announced it has dosed the first subject in a Chinese Phase 1 trial of SRSD107, its next generation siRNA therapeutic targeting coagulation Factor XI (FXI), for the prevention and treatment of thromboembolic disorders. This study is to evaluate… Read More
Financing includes nine new investors and was led by New Enterprise Associates, Deep Track Capital, Sofinnova Investments, and Sands Capital Proceeds to support advancing AVZO-021, a potentially best-in-class cyclin-dependent kinase 2 (CDK2) selective inhibitor SAN DIEGO, Calif., March 26, 2024 – Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next… Read More
